Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BOLD

Boundless Bio Inc

Mar 12 • 03:51PM ET

1.68

Dollar change +0.08
Percentage change 5.00	%

Healthcare • Biotechnology • USA • NASD

Peers: BLUE NTLA CRSP EDIT SGMO BNGO CERS MESO FATE CLLS

| Held by: VTI IWM VTWO IWO IWC VXF IWN VTWG RSSL VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.75	Insider Own	33.25%	Shs Outstand	22.25M	Perf Week	-1.18%
Market Cap	37.46M	Forward P/E	-	EPS next Y	-3.19	Insider Trans	0.00%	Shs Float	14.88M	Perf Month	-25.66%
Income	-61.06M	PEG	-	EPS next Q	-0.73	Inst Own	52.62%	Short Float	2.75%	Perf Quarter	-40.64%
Sales	0.00M	P/S	-	EPS this Y	17.01%	Inst Trans	-2.71%	Short Ratio	4.26	Perf Half Y	-47.50%
Book/sh	7.42	P/B	0.23	EPS next Y	0.52%	ROA	-38.30%	Short Interest	0.41M	Perf Year	-
Cash/sh	7.49	P/C	0.22	EPS next 5Y	-	ROE	-249.02%	52W Range	1.55 - 15.24	Perf YTD	-42.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-36.99%	52W High	-88.98%	Beta	0.02
Dividend TTM	-	Quick Ratio	17.03	Sales past 5Y	0.00%	Gross Margin	-	52W Low	8.39%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	17.03	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	32.82	Volatility	7.23% 8.30%
Employees	72	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.67	Target Price	14.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-25.24%	Payout	-	Rel Volume	0.41	Prev Close	1.60
Sales Surprise	-	EPS Surprise	0.76%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	96.15K	Price	1.68
SMA20	-10.98%	SMA50	-24.77%	SMA200	-52.72%	Trades		Volume	38,487	Change	5.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-24	Downgrade	Guggenheim	Buy → Neutral
Apr-22-24	Initiated	Piper Sandler	Overweight	$20
Apr-22-24	Initiated	Leerink Partners	Outperform	$25
Apr-22-24	Initiated	Guggenheim	Buy	$24

Feb-26-25 07:00AM	Boundless Bio to Participate in the Leerink Global Healthcare Conference (GlobeNewswire)
Feb-03-25 10:00AM	Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Dec-12-24 04:01PM	Boundless Bio Announces Pipeline and Leadership Updates (GlobeNewswire) -12.72% -16.61%
Nov-25-24 07:00AM	Boundless Bio to Participate in the Piper Sandler Healthcare Conference (GlobeNewswire) +8.94%
Nov-07-24 04:01PM	Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +5.42%
07:00AM	Loading…
Nov-05-24 07:00AM	Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference (GlobeNewswire)
Oct-14-24 08:00AM	Boundless Bio Announces Departure of Chief Financial Officer (GlobeNewswire)
Sep-11-24 07:00AM	Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-13-24 04:28AM	Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO (FierceBiotech.com)
03:32AM	Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now? (Insider Monkey)
Aug-12-24 10:53PM	BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024 (InvestorPlace) -6.19%
04:01PM	Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-05-24 07:00AM	Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-13-24 02:53PM	BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024 (InvestorPlace) +10.83%
07:00AM	Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights (Business Wire)
08:00AM	Loading…
May-06-24 08:00AM	Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 (Business Wire)
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire)
Apr-14-24 11:37AM	Insiders are Amassing These 10 Stocks in April (Insider Monkey)
Apr-11-24 08:00AM	Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications (Business Wire)
Apr-08-24 08:00AM	Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 (Business Wire) -5.75%
Mar-27-24 06:55PM	Boundless Bio Announces Pricing of Initial Public Offering (Business Wire)

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM
CRANDELL KEITH	10% Owner	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM
ARCH Venture Fund IX, L.P.	10% Owner	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Apr 02 '24	Buy	16.00	312,500	5,000,000	1,884,787	Apr 04 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BOLD

Boundless Bio Inc

Upgrade your FINVIZ experience